[A17-67] Alectinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 03.04.2018
Project no.:
A17-67
Commission:
Commission awarded on 22.12.2017 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
First-line treatment of adults with ALK-positive advanced NSCLC (lung cancer)
Result of dossier assessment:
Hint of a non-quantifiable added benefit
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A18-30 | Alectinib (non-small-cell lung cancer) - Addendum to Commission A17-67 | Commission completed |
| A24-73 | Alectinib (NSCLC, adjuvant) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2018-06-21 A G-BA decision was published.